On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review

References

• Claxton K, Martin S, Soares M, et al. Systematic review of the literature on the cost-effectiveness threshold. 2015 [cited 2017 Nov 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK274312/
   Google Scholar
• Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27:71–14.
   PubMed Web of Science ®Google Scholar
• Schwarzer R, Rochau U, Saverno K, et al. Systematic overview of cost–effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4:485–504.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff. 2000;19:92–109.
   PubMed Web of Science ®Google Scholar
• Baker R, Chilton S, Donaldson C, et al. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Econ Policy Law. 2011;6:435–447.
   PubMed Web of Science ®Google Scholar
• Eichler H-G, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518–528.
   PubMed Web of Science ®Google Scholar
• van Loghum BS. Medicijnen Pompe en Fabry blijven vergoed. Zorg en Financiering. 2012;11:51–52.
   Google Scholar
• Coast J. Is economic evaluation in touch with society’s health values? BMJ. 2004;329:1233–1236.
   PubMed Web of Science ®Google Scholar
• Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold revised report following referees comments. 2013[cited 2017 May 17]. Available from: https://www.york.ac.uk/media/che/documents/reports/resubmitted_report.pdf'
   Google Scholar
• Ross CE, Wu C-L. The links between education and health. Am Sociol Rev. 1995;60:719–745.
   Web of Science ®Google Scholar
• Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ. 2014;24:1289–1301.
   Web of Science ®Google Scholar
• Kowalczuk A. JHPOR – is the cost-effectiveness threshold cost-effective in cancer therapy? [Internet]. [ cited 2017 Feb 14]. Available from: http://www.jhpor.com/index/artykul/pokaz/is_the_cost-effectiveness_threshold_cost-effective_in_cancer_therapy
   Google Scholar
• Gulácsi L, Rotar AM, Niewada M, et al. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ. 2014;15:S13–S25.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–725.
   PubMed Web of Science ®Google Scholar
• Borgström F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int. 2006;17:1459–1471.
   PubMed Web of Science ®Google Scholar
• WHO. Table: threshold values for intervention cost-effectiveness by region. 2014 [cited 2017 Feb 14]. Available from: http://www.who.int/choice/costs/CER_levels/en/
   Google Scholar
• Macroeconomics and health: Investing in health for economic development. Report of the commission on macroeconomics and health to the WHO [Internet].Geneva; 2001 [cited 2017 Mar 13]. Available from: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf.
   Google Scholar
• Robinson LA, Hammitt JK, Chang AY, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32:141–145.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. WHO. Thresholds for the cost–effectiveness of interventions: alternative approaches. 2015 [cited 2016 May 3]. Available from: http://www.who.int/bulletin/volumes/93/2/14-138206/en/
   Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178.
   PubMedGoogle Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–797.
   PubMed Web of Science ®Google Scholar
• Muurinen J-M. Demand for health: a generalised Grossman model – ScienceDirect [Internet]. [ cited 2017 Feb 12]. Available from: http://www.sciencedirect.com/science/article/pii/0167629682900194
   Google Scholar
• Nimdet K, Chaiyakunapruk N, Vichansavakul K, et al. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? PLoS One. 2015;10:e0122760.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012;380:2144–2162.
   PubMed Web of Science ®Google Scholar
• XE currency tables [Internet]. [ cited 2016 Apr 27]. Available from: http://www.xe.com/currencytables/
   Google Scholar
• Calculator USI. US inflation calculator. [Internet]. [cited 2018 Mar 14] Available from: http://www.usinflationcalculator.com/
   Google Scholar
• GDP per capita (current US$). Data [Internet]. [ cited 2017 Feb 14]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD
   Google Scholar
• Price level ratio of PPP conversion factor (GDP) to market exchange rate. Data [Internet]. [ cited 2017 Feb 14]. Available from: http://data.worldbank.org/indicator/PA.NUS.PPPC.RF
   Google Scholar
• Welcome to the CIA web site — Central Intelligence Agency [Internet]. [ cited 2016 May 3]. Available from: https://www.cia.gov/index.html
   Google Scholar
• Gergonne JD. The application of the method of least squares to the interpolation of sequences. Historia Math. 1974;1:439–447.
   Google Scholar
• Ngorsuraches S, Meng W, Kim B-Y, et al. Drug reimbursement decision-making in Thailand, China, and South Korea. Value Health. 2012;15:S120–S125.
   PubMed Web of Science ®Google Scholar
• OECD. “Willingness to pay vs. willingness to accept”,in cost-benefit analysis and the environment: Recent developments, OECD Publishing, Paris; 2006. p. 155–167.
   Google Scholar
• NCPE Submission Process. National Centre for Pharmacoeconomics [Internet]. [ cited 2017 Mar 15]. Available from: http://www.ncpe.ie/submission-process/
   Google Scholar
• Yazdanpanah Y, Perelman J, DiLorenzo MA, et al. Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One. 2013;8:e84173.
   PubMed Web of Science ®Google Scholar
• Paris V, Belloni A. Value in pharmaceutical pricing; 2013 [cited 2017 Feb 14]. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en;jsessionid=kskb76eb9t38.x-oecd-live-02
   Google Scholar
• Ministerie van Volksgezondheid W en S. Kosteneffectiviteit in de praktijk [Internet]. 2015 [cited 2018 Feb 21]. Available from: https://www.zorginstituutnederland.nl/publicaties/rapport/2015/06/26/kosteneffectiviteit-in-de-praktijk
   Google Scholar
• Zhao FL, Yue M, Yang H, et al. PHP31 willingness to pay per quality adjusted life-year: is one threshold applicable for all decision-making. Value Health. 2010;13:A538.
   Web of Science ®Google Scholar
• Donaldson C. Existing contingent valuation studies ofthe value of prevented fatalities and serious injuries. EuroVaQ;2010 [cited 2017 Feb 14]. Available from: http://research.ncl.ac.uk/eurovaq/EuroVaQ_Final_Publishable_Report_and_Appendices.pdf
   Google Scholar
• Gyrd-Hansen D, Kjær T. Disentangling WTP per QALY data: different analytical approaches, different answers. Health Econ. 2012;21:222–237.
   PubMed Web of Science ®Google Scholar
• Pinto-Prades JL, Loomes G, Brey R. Trying to estimate a monetary value for the QALY. J Health Econ. 2009;28:553–562.
   PubMed Web of Science ®Google Scholar
• Jef ZR, Leufkens H, Busschbach J, et al. Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands: the Dutch results from the EUROMET project. Pharmacoeconomics. 2000;18:149–160.
   Web of Science ®Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY. Pharmacoeconomics. 2005;23:423–432.
   PubMed Web of Science ®Google Scholar
• Bobinac A, van Exel NJA, Rutten FFH, et al. Inquiry into the relationship between equity weights and the value of the QALY. Value Health. 2012;15:1119–1126.
   Web of Science ®Google Scholar
• TLV. [ cited 2017 Nov 24]. Available from: https://www.tlv.se/In-English/medicines-new/apply-for-a-price-or-reimbursement/the-decision-process/
   Google Scholar
• Five drugs rejected by NICE [Internet]. Pharmaceutical Journal. Royal Pharmaceutical Society; [ cited 2017 Jun 15]. Available from: http://www.pharmaceutical-journal.com/news-and-analysis/five-drugs-rejected-by-nice/11037465.article
   Google Scholar
• Wasserman E. Look out, drugmakers: NICE is taking the reins of England’s cancer drugs fund [Internet]. 2016 [cited 2017 Jun 15]. Available from: http://www.fiercepharma.com/regulatory/look-out-drugmakers-nice-taking-reins-of-england-s-cancer-drugs-fund
   Google Scholar
• LaBar M. The Blackwell guide to medical ethics [Internet]. Association of College and Research Libraries; 2007 [cited 2016 May 7]. Available from: http://www.cro3.org/content/45/01/45-0307
   Google Scholar
• Bobinac A, van Exel J, Rutten FFH, et al. The value of a QALY: individual willingness to pay for health gains under risk. Pharmacoeconomics. 2014;32:75–86.
   PubMed Web of Science ®Google Scholar
• Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2013;5:29–36.
   PubMedGoogle Scholar
• Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc. 2013;11:22.
   PubMedGoogle Scholar
• Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80.
   PubMedGoogle Scholar
• Donaldson C, Birch S, Gafni A. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. Health Econ. 2002;11:55–70.
   PubMed Web of Science ®Google Scholar
• Ataguba, J, Ichoku EH, Fonta W, et al. An estimation of the willingness-to-pay for community healthcare risk-sharing prepayment scheme and the medical poverty Trap: evidence from rural Nigeria. A paper presented during the 5th PEP Research Network General Meeting PEP Research Network; 2006 [cited Nov 11 2016]. Available from: http://anciensite.pep-net.org/fileadmin/medias/pdf/files_events/5th_ethiopia/John_Ataguba.pdf
   Google Scholar
• Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–437.
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003;12:1049–1060.
   PubMed Web of Science ®Google Scholar
• King JT Jr, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25:667–677.
   PubMed Web of Science ®Google Scholar
• O’Brien B, Gafni A. When do the “dollars” make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making. 1996;16:288–299.
   PubMed Web of Science ®Google Scholar
• Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology. 1999;38:807–813.
   PubMed Web of Science ®Google Scholar
• Boyd NF, Sutherland HJ, Heasman KZ, et al. Whose utilities for decision analysis? Med Decis Making. 1990;10:58–67.
   PubMed Web of Science ®Google Scholar
• Bobinac A, Ana B, van Exel NJA, et al. Valuing QALY gains by applying a societal perspective. Health Econ. 2012;22:1272–1281.
   Web of Science ®Google Scholar
• Figueras J, McKee M, Mossialos E, et al. Social healthcare systems in Western Europe. Open University Press. [Internet]; 2004; [cited 2016 Nov 11]. Available from: http://www.who.int/health_financing/documents/shi_w_europe.pdf
   Google Scholar